Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MediciNova, Inc. - Common Stock
(NQ:
MNOV
)
1.740
-0.840 (-32.55%)
Streaming Delayed Price
Updated: 11:43 AM EDT, Sep 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MediciNova, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
Today 10:30 EDT
Via
Chartmill
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
Today 6:00 EDT
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
September 24, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
Unusual volume stocks in Tuesday's session
↗
September 22, 2026
Via
Chartmill
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’
↗
October 30, 2025
Via
Stocktwits
Unusual volume stocks in Monday's session
↗
September 21, 2026
Via
Chartmill
Unusual volume stocks in Friday's session
↗
September 18, 2026
Via
Chartmill
MediciNova to Participate in Two Investor Conferences in September
September 08, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
July 15, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova CEO Provides Shareholder Update
June 30, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
June 08, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
May 26, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
April 27, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova to Participate at the 38th Annual ROTH Conference
March 16, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
January 29, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
2026 New Year’s Greetings from the CEO
January 06, 2026
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
December 18, 2025
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
December 08, 2025
From
MediciNova, Inc.
Via
GlobeNewswire
Message from the CEO to MediciNova Shareholders
December 01, 2025
Strengthening MN-001’s Scientific Foundation and Clinical Outlook
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
November 18, 2025
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 07, 2025
Via
Benzinga
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
November 06, 2025
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
November 04, 2025
From
MediciNova, Inc.
Via
GlobeNewswire
Unusual volume stocks in Monday's session
↗
November 03, 2025
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Via
Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 31, 2025
Via
Benzinga
Which stocks are experiencing notable movement on Friday?
↗
October 31, 2025
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
These stocks have an unusual volume in today's session
↗
October 31, 2025
In today's session, these stocks are experiencing unusual volume.
Via
Chartmill
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
↗
October 31, 2025
Via
Benzinga
Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?
↗
October 30, 2025
MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of promising research.
Via
Benzinga
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
October 30, 2025
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients
From
MediciNova, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
